|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
DAEHWA PHARMA CO.,LTD.
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name DAEHWA PHARMA CO.,LTD. Headquarters Gangwon 495; Asan; Chungcheongnam; 225804 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational Financial Auditors: CHUNJI (2011) Incorporation Date: January 19, 1989 Total Employees: 300 Tel: 033-342-5140 |
|
Company Description |
| Business volume decreased from the year-earlier period with a slump in sales with main products such as Cepacler capsule and Brometin capsule despite expanding OEM sales.Profitability decreased from the year-earlier period with expanding share of low-margin products while sales and admin expenses including promotion and advertising expenses increased.Financial structure remains strong with stable operating cash flow and solid capital structure. Sales will be recovered with enhanced technology as | ||
|
||
Company Analysis |
| According to the Individual - Audited financial statement for the first half of 2012, total net operating revenues decreased with -9.83%, from KRW 31,796,778 thousands to KRW 28,669,599 thousands. Operating result decreased from KRW 4,228,429 thousands to KRW 1,949,685 thousands which means -53.89% change. The results of the period decreased -45.42% reaching KRW 1,041,434 thousands at the end of the period against KRW 1,908,146 thousands last year. Return on equity (Net income/Total equity) went from 3.29% to 1.77%, the Return On Asset (Net income / Total Asset) went from 1.71% to 0.96% and the Net Profit Margin (Net Income/Net Sales) went from 6.00% to 3.63% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 83.92% compared to 92.85% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 1.82 to 1.76 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Y (non-cons) |
2012 H1 (non-cons) |
|
 | ||
| Audited | Audited | |
| ||
| KR listed company financials | KR listed company financials | |
| ||
| Unit | Thousands | Thousands |
| ||
Balance Sheet
| ||
Total Assets |
106,810,663 |
107,975,878 |
| ||
Current Assets |
38,785,564 |
42,530,047 |
| ||
Total Liabilities |
45,544,726 |
49,267,465 |
| ||
Shareholders Equity |
61,265,937 |
58,708,413 |
| ||
Current Liabilities |
18,120,170 |
24,202,046 |
| ||
| * All the accounts are in KRW. | ||
Income Statement
| ||
Total Operating Revenue |
60,173,545 |
28,669,599 |
| ||
Operational Profit (Loss) |
5,690,282 |
1,949,685 |
| ||
Net Profit (Loss) |
2,279,203 |
1,041,434 |
| ||
| * All the accounts are in KRW. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
2.13% |
0.96% |
| ||
Return on Equity (ROE) |
3.72% |
1.77% |
| ||
Return on Sales (ROS) |
3.79% |
3.63% |
| ||
Return on Capital |
2.57% |
1.24% |
| ||
Gross Profit Margin |
46.99% |
43.91% |
| Efficiency Ratios | ||
| ||
Current asset turnover |
1.55x |
0.67x |
| ||
Asset Turnover |
0.56x |
0.27x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
-1,037,460 |
-870,686 |
| ||
EBITDA |
5,794,101 |
2,000,385 |
| ||
Bookvalue (BV) |
60,233,318 |
57,661,620 |
| Liquidity Ratios | ||
| ||
Current Ratio |
214.05% |
175.73% |
| ||
Quick ratio |
162.58% |
134.7% |
| ||
Doom's day ratio |
6.12% |
6.87% |
| ||
Cash Flow to Debt |
-0.22% |
0.92% |
| Leverage Ratios | ||
| ||
Leverage ratio |
174.34% |
183.92% |
| ||
Interest Coverage Ratio |
317.18% |
311.73% |
| ||
Debt to equity |
74.34% |
83.92% |
| ||
Debt to total assets |
42.64% |
45.63% |
| ||
Long Term Debt to Capital |
30.92% |
29.92% |
| Market ratios | ||
| ||
Price/Book Ratio |
2.06 |
1.90 |
| Trend Ratios | ||
| ||
Revenue Trend |
97.01% |
90.17% |
| ||
Net Income Trend |
84.03% |
54.58% |
| ||
 |